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Abstract Mutations in the ATP13A2 (PARK9) and FBXO7
(PARK15) genes are linked to different forms of autosomal
recessive juvenile-onset neurodegenerative diseases with
overlapping phenotypes, including levodopa-responsive
parkinsonism, pyramidal disturbances, cognitive decline,
and supranuclear gaze disturbance. However, the associated
genotypes and phenotypes are poorly characterized due to
the small number of patients described. Here, we report
clinical, instrumental, and genetic findings in an Italian
family with novel PARK9 and PARK15 mutations. The
proband developed a severe progressive phenotype includ-
ing juvenile-onset parkinsonism, pyramidal disturbances,
cognitive decline, and oculomotor abnormalities. On the
contrary, his brother only shows mild abnormalities
(pyramidal, cognitive, and oculomotor) on the neurological
examination at the age of 31 years. These two brothers both
carry a novel homozygous PARK9 missense (p.G877R) and
a novel heterozygous PARK15 mutation (p.R481C). The
PARK9 mutation replaces a crucial residue for the ATPase
activity, and is therefore most likely a loss-of-function
mutation and disease-causing in homozygous state. The
pathogenic significance of the PARK15 single heterozygous
mutation remains unclear. In both sibs, DaTSCAN single
photon emission computed tomography showed marked
nigrostriatal dopaminergic defects, and transcranial mag-
netic stimulation detected prolonged central motor conduc-
tion time. MRI, including T2*-weighted imaging, detected
no evidence of brain iron accumulation. This family, the
third reported with homozygous PARK9 mutations and the
first with mutations in two genes for atypical juvenile
parkinsonism, illustrates that PARK9-linked disease might
display wide intra-familial clinical variability and milder
phenotypes, suggesting the existence of strong, still
unknown, modifiers.
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Introduction
PARK9, or Kufor-Rakeb syndrome (KRS), is character-
ized by juvenile-onset, levodopa-responsive parkinsonism,
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[1, 2], caused by recessive mutations in the ATP13A2 gene
[3]. Since the initial report, only six definitely disease-
causing (homozygous or compound heterozygous) muta-
tions have been described in two families [3] and three
isolated KRS patients [4–6]. For another seven mutations
identified in single heterozygous state in patients with
early-onset Parkinson’s disease (PD) [4, 7, 8], the role in
the disease causation remains unclear.
The ATPA13A2 gene encodes a large lysosomal trans-
membrane protein, belonging to the group 5 P-type ATPase
family. P-type ATPases use the energy deriving from ATP
hydrolysis to generate gradients of ions across membranes
[9]. The substrate specificity of the ATP13A2 protein
remains unknown, but there is evidence that this protein is
involved in the transport of several cations from the cytosol
to the lysosomal lumen, including manganese, cadmium,
nickel, and selenium [10, 11].
Recessive mutations in the FBXO7 gene have been
recently linked to PARK15, a different rare juvenile
neurodegenerative disorder, presenting as a parkinsonian-
pyramidal syndrome and reported so far in only three
families [12, 13].
In this study, we describe two brothers from a southern
Italian family, who both carry a novel homozygous
ATP13A2 mutation and a single heterozygous FBXO7
mutation. Despite the identical genotypes, the brothers
were affected with markedly different severity.
Subjects and methods
A simplified pedigree is shown in Fig. 1. A healthy couple
had two offspring, who both developed different degrees of
a progressive neurological disease. The parents report no
known consanguinity, but they both originate from the
same small village in the Campania region of southern
Italy. The project was approved by the relevant ethical
authorities, and written informed consent was obtained
from all subjects.
Genetic studies
Genomic DNA was isolated from peripheral blood samples
following standard procedures. We first screened the
proband for mutations in the parkin (PARK2), PINK1
(PARK6), DJ-1 (PARK7), ATP13A2 (PARK9), PLA2G6
(PARK14), and FBXO7 (PARK15) genes. All exons and
exon–intron boundaries of the above-mentioned genes were
sequenced in both strands. The PCR protocols and primers
are available on request from the authors. Direct sequencing
was performed using Big Dye Terminator chemistry ver.3.1
(Applied Biosystems). Fragments were loaded on an
Applied Biosystems 3130XL automated sequencer and
analyzed with DNA Sequencing Analysis (ver.5.3) and
SeqScape (ver.2.6) software (Applied Biosystems). The
mutations were numbered from the “A” of the ATG-
translation initiation codon, according to the GenBank
reference sequences, accession numbers NM_022089.2
(ATP13A2) and NM_012179.3 (FBXO7). We also screened
the proband for copy number aberrations in the parkin,
PINK1, DJ-1, ATP13A2,a n dSNCA (alpha-synuclein)
genes, using a multiplex ligation-dependent probe amplifi-
cation (MLPA) assay (probe mix P051 and P052) according
to the manufacturer’s protocol (MRC-Holland). The PARK9
and PARK15 mutations detected in the proband were
studied in the whole family, as well as in a panel of
unrelated healthy controls from the same region of southern
Italy, and using the same sequencing techniques. In order to
analyze the evolutionary conservation of the mutated amino
acids, the ATP13A2 and FBXO7 protein homologues were
aligned using the program ClustalW.
Brain imaging
Brain single photon emission computed tomography
(SPECT) studies were performed 4 h after intravenous
administration of 185 MBq of [123I]FP-CIT (DaTSCAN,
GE-Healthcare) using a dual-headed camera (E.CAM,
Siemens Medical Systems, Hoffman Estates, IL) equipped
with low-energy high-resolution collimators (zoom, 1.23;
pixel size, 3.90×3.90 mm). Outcome measures were the
specific-to-nondisplaceable binding ratio, V″3 for the puta-
men and caudate.
The brain MRI studies included T2-weighted turbo spin-
echo (TSE) (TR/TE 4,400/100 ms) and FLAIR (TR/TE/TI
8,000/100/2,200 ms) sequences, as well as T1-weighted
conventional SE (TR/TE 580/15 ms), and DWI (EPI, TR/
TE 3,500/90 ms) images (1.5 T, Achieva, Philips Medical
Systems, Eindhoven, Netherlands). In addition, T2*-
weighted axial images (Gradient echo, TR/TE 600/15 ms,
Flip Angle 20°) were acquired (3 T, Magnetom Trio,
Siemens Medical Systems, Erlangen, Germany).
Results
Clinical findings
The proband (NAPO-6 in Fig. 1) is a 41-year-old man with
referred perinatal asphyxia and slight delay in reaching the
developmental milestones. At the age of 10 years, he
developed a slowly progressive gait disturbance with
slowing and stiffness of legs. An asymmetric onset of
symptoms was not recorded. Treatment with levodopa
yielded marked improvement in gait and in limb rigidity.
34 Neurogenetics (2011) 12:33–39Nonetheless, over time, his motor performance progres-
sively deteriorated, and a mild cognitive impairment
became apparent. At the age of 18 year, he received the
diagnosis of “extra-pyramidal and pyramidal syndrome
with cognitive impairment”. Since then, the patient com-
plained of dysarthria and dysphagia, and some years later,
the arm and leg stiffness became so severe to determine the
complete dependence on others for all daily living
activities. Our neurological examination, 30 years after the
disease onset, showed a moderate limitation of the up-gaze
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Fig. 1 Genetic findings in the family with PARK9 and PARK15
mutations. a Electropherograms of a fragment of ATP13A2 (PARK9)
exon 24; hom homozygous mutation, het heterozygous mutation, wt
wild-type sequence. b Simplified pedigree. The proband is highlighted
by a black symbol; his brother is highlighted in gray. The ATP13A2
(PARK9) and FBXO7 (PARK15) mutations are shown below the
individual symbols. c Electropherograms of a fragment of FBXO7
(PARK15) exon 9; het heterozygous mutation, wt wild-type sequence.
d Schematic representation of the ATP13A2 protein, its known
functional domains and amino acid motifs. The position of the
G877R mutation detected in the Italian family is indicated within the
P2 domain and within the MCGDG motif (the mutated G is
underlined). The other two missense mutations reported previously
in homozygous state in PARK9 patients are also shown. e Schematic
representation of the FBXO7 protein. The R481C mutation detected in
the Italian family is framed. The other disease-causing mutations
reported previously in PARK15 patients are also shown. f Alignment
of ATP13A2 protein homologues in the region of the G877R mutation.
g Alignment of P5-ATPase protein family in the region corresponding
to the G877R mutation. h Alignment of FBXO7 protein homologues
in the region of the R481C mutation
Neurogenetics (2011) 12:33–39 35and right lateral gaze. The saccadic eye movements were
slow both in upward and downward direction and bilater-
ally hypometric on lateral gaze. A severe hypomimia was
present, and the speech was almost incomprehensible.
There was also mild dysphagia, allowing a normal feeding.
Sub-continuous mini-myoclonus was present in the lower
facial muscles. The gait was only possible with bilateral
support, and dystonic posturing was present. The muscle
tone was markedly increased in all limbs with prevalence of
rigidity in the arms and spasticity in the legs. The deep
tendon reflexes were all brisk, and the Babinski sign and
palmomental reflex were present bilaterally. Cerebellar
signs and tremor were absent. The unified PD rating scale
(UPDRS) motor score was 67, and it was not modified by
the acute administration of levodopa. The administration of
the mini-mental state examination (MMSE) was not
possible. Blood chemistry, including manganese, selenium,
cadmium, and nickel dosage, was normal. Needle EMG
(biceps brachii, rectus femori, and tibialis anterior muscles),
surface antidromic sensory (median, ulnar, sural, and
peroneal nerves) and orthodromic motor nerve (median,
ulnar, and tibial nerves) conduction studies (NCS), and
somatosensory evoked potentials (SSEPs) following medi-
an and tibial nerve were all normal. Transcranial Magnetic
Stimulation (TMS) showed a prolonged central motor
conduction time (CMCT) for upper (10.3 ms; normal upper
limit, 8 ms) and lower (30.5 ms; normal upper limit, 15 ms)
limbs, while motor evoked potential (MEP) amplitude was
normal in the upper and reduced in the lower limbs
(0.7 mV; normal lower limit, 1.2 mV).
The proband’s brother (NAPO-7 in Fig. 1), a 31-year-old
man, had a normal birth and developmental motor mile-
stones, but he did not perform normally at school and
received a diagnosis of “mild mental retardation”. At the
time of neurological examination (age 31), he was
otherwise asymptomatic. However, the neurological evalu-
ation showed a slight limitation of upward and downward
gaze, moderate increase of axial tone, and slight upper limb
rigidity. The deep tendon reflexes were brisk, and the
Babinski sign was bilaterally present. Finger tapping and
stepping were moderately decreased in frequency and
amplitude. Cerebellar signs and tremor were absent. The
UPDRS motor score was 16. He had never used anti-
parkinsonian drugs. The MMSE score was 23. Blood
chemistry, including manganese, selenium, cadmium, and
nickel dosage, was normal. Needle EMG (biceps brachii,
rectus femori, and tibialis anterior muscles), surface
antidromic sensory (median, ulnar, sural, and peroneal
nerves) and orthodromic motor (median, ulnar, and tibial
nerves) NCS, and SSEPs following median and tibial nerve
were normal. TMS showed a prolonged CMCT for upper
(11.8 ms; normal upper limit, 8 ms) and lower (24.2 ms;
normal upper limit, 15 ms) limbs, while MEP amplitude
was normal in the upper and reduced in the lower limbs
(0.4 mV; normal lower limit, 1.2 mV).
Genetic findings
By sequencing the genomic DNA in the proband, we
detected a homozygous mutation in exon 24 of the ATP13A2
gene (c.G2629A, predicted to lead to the p.G877R missense
change in the encoded protein) and a heterozygous
mutation in exon 9 of the FBXO7 gene (c.C1441T,
predicted to result in the missense change p.R481C)
(Fig. 1a–c). Direct sequencing revealed no additional
mutations in these or other screened genes for autosomal
recessive parkinsonism (parkin, PINK1, DJ-1, PLA2G6).
Furthermore, gene dosage aberrations were not detected by
the MLPA assays in any of the screened genes. The
ATP13A2 c.G2629A mutation was detected in heterozy-
gous state in both the proband’s parents, while it was absent
from a large number of control chromosomes (n=336) from
the same region of southern Italy. The FBXO7 c.C1441T
mutation was detected in heterozygous state in the pro-
band’s mother, while it was absent from the father and from
control chromosomes from the region (n=318). The
proband’s brother (NAPO-7) carried a homozygous
ATP13A2 and heterozygous FBXO7 mutation, a situation
identical to that found in the proband (Fig. 1b). The cDNA
studies confirmed the genotypes detected in genomic DNA
in the whole family (not shown). Both mutations introduce
drastic replacements in amino acid positions that have been
highly conserved in the evolution of the ATP13A2 and
FBXO7 protein homologues (Fig. 1d–h).
Imaging findings
The [123I]FP-CIT–SPECT showed in both brothers a
decrease of dopamine transporter (DaT) density in the
striatum (Fig. 2). Compared to controls, the proband
showed a marked and widespread striatal reduction of V″3
(75% in the caudate and 85% in the putamen) (Fig. 2a). In
the brother, the specific-to-nondisplaceable binding ratio
V″3 was also symmetrically reduced, mostly in the puta-
men (40% in the caudate and 65% in the putamen)
(Fig. 2b). In both brothers the brain MRI showed diffuse
cerebral and cerebellar cortex atrophy, which was more
severe in the proband (Fig. 3). The T2* scans detected no
evidence of metal accumulation in the basal ganglia of
both sibs (Fig. 3c, f).
Discussion
Several arguments support the view that the G877R
mutation is harmful for the ATP13A2 protein function.
36 Neurogenetics (2011) 12:33–39The glycine 877 lies in a stretch of five amino acids that
have not only been conserved in the evolution of ATP13A2
homologues until the yeasts but are also invariably present
in all members of the ATPase P5 protein family (Fig. 1f–g),
suggesting a crucial role for the protein function. Further-
more, the G877R mutation replaces a small non-polar
amino acid (glycine) with a larger polar one (arginine). The
large cytoplasmic loop located between the M4 and M5
Fig. 2 DaTSCAN SPECT im-
aging. Brain [123I]FP-CIT
(DaTSCAN SPECT) in the pro-
band (a), his brother (b), and a
normal unrelated subject (c); a
severe presynaptic defect of the
nigrostriatal dopaminergic
systems is present in the two
brothers, more marked in the
proband
Fig. 3 Brain MRI imaging.
T2-weighted TSE axial scans
(1.5 T) at the level of the
cerebellar hemispheres (a, d)
and centra semiovalia (b, e) and
T2*-weighted scans (3 T) at the
level of the basal ganglia (c, f),
in the proband (a–c) and his
brother (d–f). Diffuse supra- and
sub-tentorial atrophy is present.
The T2*-weighted scans show
normal intensity of the basal
ganglia in both individuals. In-
cidental left maxillary sinusitis
is also present (d)
Neurogenetics (2011) 12:33–39 37transmembrane domains of the ATP13A2 protein (Fig. 1d)
contains the catalytic autophosphorylation domain (P
domain, including an N-terminal and C-terminal part) and
the nucleotide binding domain (N domain, necessary for
ATP binding) [9, 14]. The presence of an arginine in
position 877 places a net positive charge next to the highly
conserved negatively charged aspartic acid in position 878,
in a very important motif within the C-terminal part of the P
domain (Fig. 1d).
Structural studies of a similar P-type cationic pump, the
calcium ATPase of skeletal muscle sarcoplasmic reticulum
(SERCA1), revealed that the conserved aspartic acid
corresponding to Asp-878 in ATP13A2 is one of the most
critical residues for the ATP hydrolysis and is spatially very
close to the aspartic acid residue (Asp351, corresponding to
Asp513 in ATP13A2) which provides the autophosphor-
ylation site [14]. Thus, the G877R mutation is very likely to
interfere with the ATPase and autophosphorylation activity
of ATP13A2, necessary for the function as cationic pump.
Taken together, these considerations argue strongly that the
G877R mutation is deleterious for the ATP13A2 function
and disease-causing when present in homozygous state.
The R481C mutation replaces a highly conserved
arginine residue in the FBXO7 protein, within the so called
R(Ar)DP motif (where Ar indicates any aromatic amino
acid) in the C-terminal proline-rich region of the protein
(Fig. 1e, h)[ 15]. The function of the R(Ar)DP motif remains
undetermined, but the proline-rich region is important for
binding of the known FBXO7 substrates [15–17]. The
mutation might therefore also be deleterious for the FBXO7
function. However, being found as a single heterozygous
mutation in the two affected brothers and their unaffected
mother, its significance for the disease causation remains
unclear. This could be a coincidental finding, or the mutation
could act as a disease modifier, or play some pathogenic role,
together with still unknown mutations in other genes.
Different research lines point to an important role for the
lysosomes in the pathogenesis of common, late-onset PD.
Lysosomes are important for the degradation of the alpha-
synuclein protein [18], and heterozygous mutations in the
GBA gene, encoding the lysosomal enzyme glucocerebro-
sidase, are an important risk factor for PD [19]. Intriguing-
ly, the ATP13A2 mRNA is highly expressed in the brain,
particularly in substantia nigra, and it might be up-regulated
in the brain of patients with the common late-onset
idiopathic PD [3]. Moreover, the ATP13A2 protein has
been recently identified as a potent modifier of the toxicity
induced by alpha-synuclein in animal models of PD [10].
On the other hand, manganese, one possible substrate of
ATP13A2, is a well-known cause of toxic parkinsonism in
humans [20]. Despite the rarity of PARK9 mutations, the
ATP13A2 protein might therefore offer clues for under-
standing the pathogenesis of the common, late-onset forms
of PD, linking genetic (alpha-synuclein), and environmental
(manganese) factors in the disease etiology.
The clinical phenotype associated with PARK9 mutations
remains poorly defined, as only few patients with clear
disease-causing genotypes have been reported. Some
phenotypic variability has been described (i.e., variable
presence and degrees of dementia, behavior disorders,
visual hallucinations, L-dopa responsiveness, and disease
progression). Our proband resembles indeed the previously
reported PARK9 cases, and his phenotype is compatible
with the clinical diagnosis of KRS. The sub-continuous
mini-myoclonus present in the lower facial muscles is
reminiscent of the facial–faucial–finger mini-myoclonus
described in the original KRS patients [2] and other PARK9
cases [3, 5]. Remarkably, the younger brother, apart from a
moderate cognitive deficit, remains otherwise asymptomat-
ic at the age of 31 years, and only the neurological
examination revealed a mild pyramidal–extra-pyramidal
involvement. This marked phenotypic variability has not
been previously described in patients with identical PARK9
mutations. It could be the result of the action of genetic or
environmental modifiers, or both. An aggravating effect for
the perinatal brain sufferance in the proband could not be
excluded; however, the severity of his phenotype is similar
to that in the other PARK9 patients, and therefore, a
protective effect in the proband’s brother appears more
likely. Mutations in the other known genes for early-onset
PD (apart from the FBXO7 heterozygous mutation) were
excluded in the proband, and therefore they cannot play a
role as aggravating factors. Environmental factors could
include the role of some cations, according to the evidence
that the ATP13A2 protein is involved in their transport
from the cytosol to the lysosomal lumen [10, 11]. However,
the blood levels of manganese, cadmium, nickel, and
selenium were normal in both sibs. Furthermore, the
siblings have been living with their parents in the same
place, being likely exposed to the same environment.
In both sibs, the brain MRI showed diffuse brain
atrophy, more marked in the proband, and the DaTSCAN
SPECT showed marked nigrostriatal dopaminergic defects,
again more marked in the proband, and similar to those
reported in advanced idiopathic PD. The neurophysiologic
investigation confirmed the involvement of the pyramidal
tract and showed the normality of the large myelinated
peripheral fibers and of the somatosensory system.
Recently, hypointense signals in the basal ganglia in
MRI T2*-weighted scans, suggesting iron accumulation,
have been reported in a patient with homozygous PARK9
mutation [6]. Based on this finding, it has been suggested to
classify PARK9 within the neurodegenerations with brain
iron accumulation [6]. The MRI studies in other previously
reported PARK9 cases did not include T2*-weighted scans
[2, 5] and were therefore inconclusive concerning the iron
38 Neurogenetics (2011) 12:33–39accumulation. Using a comprehensive MRI protocol that
includes T2*-weighted scans, we did not find evidence of
metal accumulation in the basal ganglia of both sibs
reported here. Brain metal accumulation seems therefore
not a constant feature in PARK9, even after three decades
of disease course. Perhaps brain metal accumulation occurs
in the cases with ATP13A2 mutations leading to the most
severe loss of protein function, such as that present in the
patient reported elsewhere [6] (p.Thr367ArgfsX29, causing
frameshift and protein truncation), while in some patients
with missense mutations a residual protein function is
retained and brain metal accumulation does not occur.
In conclusion, this family, the third reported with
homozygous PARK9 mutations and the first with mutations
in two genes for atypical juvenile parkinsonism, illustrates
that PARK9-linked disease might display wide intra-familial
clinical variability and present with milder phenotypes,
suggesting the existence of strong, still unknown, modifiers.
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